UT MD Andreson Cancer Center
Welcome,         Profile    Billing    Logout  
 63 Trials 
18 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Valero, Vicente
NCT05035836: A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Recruiting
2
20
US
Zanidatamab, ZW25, Letrozole, Tamoxifen
M.D. Anderson Cancer Center, Zymeworks BC Inc.
Breast Cancer, HER2-positive
12/25
12/25
ATEMPT 2.0, NCT04893109: Adjuvant T-DM1 Vs TH

Recruiting
2
500
US
trastuzumab-emtansine, T-DM1, Kadcyla, Trastuzumab SC, Herceptin Hylecta, Paclitaxel, Taxol, Onxal
Dana-Farber Cancer Institute, Genentech, Inc.
Breast Cancer, HER2-positive Breast Cancer
05/25
05/28
ADEPT, NCT04569747: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Recruiting
2
375
US
Pertuzumab+TRASTUZUMAB, PHESGO, ADJUVANT ENDOCRINE THERAPY, Letrozole, Anastrozole, Exemestane, Tamoxifen, Leuprolide, or other LHRH agonist (per investigator discretion)
Dana-Farber Cancer Institute, Genentech, Inc.
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
09/26
09/30
Li, Jing
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting
4
8250
RoW
Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy
Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases
04/25
04/25
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF
Terminated
3
372
Europe, US, RoW
Pamrevlumab, FG-3019, Placebo
FibroGen
Idiopathic Pulmonary Fibrosis
09/23
09/23
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

Terminated
2
6
RoW
Infigratinib, BGJ398, BBP-831
LianBio LLC
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
05/24
05/24
AGE-M, NCT06459310: Pilot Study on Evaluating the Geroprotective Effect of Metformin

Recruiting
2
130
RoW
Metformin Hydrochloride tablet, Metformin, Placebo
Xuanwu Hospital, Beijing, Institute of Zoology, Chinese Academy of Sciences, Beijing Institute of Genomics, Chinese Academy of Sciences, Merck Serono Co., Ltd., China
Metformin, Aging
09/26
07/28
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Completed
2
305
RoW
SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan
Shanghai Pharmaceuticals Holding Co., Ltd
Diabetic Kidney Disease
12/24
12/24
FRUSICA-1, NCT03903705: : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Completed
1/2
348
RoW
Fruquintinib in Combination with Sintilimab, Fruquintinib
Hutchmed
Advanced Solid Tumor
11/23
12/24
SAFE-APD, NCT03598387: Automated Peritoneal Dialysis Versus Intermittent Hemodialysis in Acute Kidney Injury

Recruiting
N/A
100
RoW
Automated peritoneal dialysis, Intermittent hemodialysis
Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation
Acute Kidney Injury
12/22
12/22
NCT06025045: Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments

Recruiting
N/A
50
RoW
Jing Li, Nanjing Shihejiyin Technology, Inc.
Ovarian Cancer Stage IV, Ovarian Cancer Stage III
08/25
08/25
Amaria, Rodabe N
SUPRAME, NCT06743126: -ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Recruiting
3
360
Europe, US
IMA203, nivolumab plus relatlimab, Opdualag®, lifileucel, AMTAGVI, nivolumab, Opdivo®, pembrolizumab, Keytruda®, ipilimumab, Yervoy, Dacarbazine, DTIC-Dome, temozolomide, Temodar, paclitaxel, Taxol, paclitaxel plus carboplatin, Carbo/Taxol®, Albumin-Bound Paclitaxel, Abraxane®
Immatics US, Inc.
Melanoma, Cutaneous Malignant
01/28
10/31
NCT00338377: Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Active, not recruiting
2
1230
US
Dendritic Cell Immunization, Cyclophosphamide, Cytoxan, Neosar, Fludarabine, Fludarabine Phosphate, Fludara, T-Cells, Interleukin-2, IL-2, Proleukin, Mesna, Sodium 2-mercaptoethanesulfonate, Mesnum, Mesnex, NSC-113891, Intrathecal T-Cells, Intrathecal Interleukin-2
M.D. Anderson Cancer Center, Prometheus Laboratories, Key Biologics, LLC, National Cancer Institute (NCI), Adelson Medical Research
Melanoma
02/30
02/30
NCT06237881: A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Active, not recruiting
1/2
15
US
KSQ-001EX, Interleukin-2, IL-2, Cyclophosphamide, Fludarabine
M.D. Anderson Cancer Center, KSQ Therapeutics, Inc.
Advanced Solid Tumor, Melanoma, Lung Neoplasms, Head and Neck Neoplasms
01/27
01/29
NCT06598371: A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

Recruiting
1/2
141
US
Cyclophosphamide, Fludarabine, KSQ-004EX, Interleukin-2, IL-2
M.D. Anderson Cancer Center, KSQ Therapeutics, Inc.
Select Advanced Solid Tumors
08/39
08/41
Agni-01, NCT06060613: Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Recruiting
1/2
52
US
OBX-115
Obsidian Therapeutics, Inc.
Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
10/25
10/27
Nautilus, NCT05340621: NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

Completed
1/2
36
US
OKI-179 + binimetinib
OnKure, Inc.
RAS Mutation, NRAS Gene Mutation, Melanoma
01/25
01/25
Davies, Michael
No trials found
Parmar, Simrit
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Valero, Vicente
NCT05035836: A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Recruiting
2
20
US
Zanidatamab, ZW25, Letrozole, Tamoxifen
M.D. Anderson Cancer Center, Zymeworks BC Inc.
Breast Cancer, HER2-positive
12/25
12/25
ATEMPT 2.0, NCT04893109: Adjuvant T-DM1 Vs TH

Recruiting
2
500
US
trastuzumab-emtansine, T-DM1, Kadcyla, Trastuzumab SC, Herceptin Hylecta, Paclitaxel, Taxol, Onxal
Dana-Farber Cancer Institute, Genentech, Inc.
Breast Cancer, HER2-positive Breast Cancer
05/25
05/28
ADEPT, NCT04569747: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Recruiting
2
375
US
Pertuzumab+TRASTUZUMAB, PHESGO, ADJUVANT ENDOCRINE THERAPY, Letrozole, Anastrozole, Exemestane, Tamoxifen, Leuprolide, or other LHRH agonist (per investigator discretion)
Dana-Farber Cancer Institute, Genentech, Inc.
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
09/26
09/30
Li, Jing
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting
4
8250
RoW
Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy
Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases
04/25
04/25
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF
Terminated
3
372
Europe, US, RoW
Pamrevlumab, FG-3019, Placebo
FibroGen
Idiopathic Pulmonary Fibrosis
09/23
09/23
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

Terminated
2
6
RoW
Infigratinib, BGJ398, BBP-831
LianBio LLC
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
05/24
05/24
AGE-M, NCT06459310: Pilot Study on Evaluating the Geroprotective Effect of Metformin

Recruiting
2
130
RoW
Metformin Hydrochloride tablet, Metformin, Placebo
Xuanwu Hospital, Beijing, Institute of Zoology, Chinese Academy of Sciences, Beijing Institute of Genomics, Chinese Academy of Sciences, Merck Serono Co., Ltd., China
Metformin, Aging
09/26
07/28
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Completed
2
305
RoW
SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan
Shanghai Pharmaceuticals Holding Co., Ltd
Diabetic Kidney Disease
12/24
12/24
FRUSICA-1, NCT03903705: : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Completed
1/2
348
RoW
Fruquintinib in Combination with Sintilimab, Fruquintinib
Hutchmed
Advanced Solid Tumor
11/23
12/24
SAFE-APD, NCT03598387: Automated Peritoneal Dialysis Versus Intermittent Hemodialysis in Acute Kidney Injury

Recruiting
N/A
100
RoW
Automated peritoneal dialysis, Intermittent hemodialysis
Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation
Acute Kidney Injury
12/22
12/22
NCT06025045: Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments

Recruiting
N/A
50
RoW
Jing Li, Nanjing Shihejiyin Technology, Inc.
Ovarian Cancer Stage IV, Ovarian Cancer Stage III
08/25
08/25
Amaria, Rodabe N
SUPRAME, NCT06743126: -ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Recruiting
3
360
Europe, US
IMA203, nivolumab plus relatlimab, Opdualag®, lifileucel, AMTAGVI, nivolumab, Opdivo®, pembrolizumab, Keytruda®, ipilimumab, Yervoy, Dacarbazine, DTIC-Dome, temozolomide, Temodar, paclitaxel, Taxol, paclitaxel plus carboplatin, Carbo/Taxol®, Albumin-Bound Paclitaxel, Abraxane®
Immatics US, Inc.
Melanoma, Cutaneous Malignant
01/28
10/31
NCT00338377: Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Active, not recruiting
2
1230
US
Dendritic Cell Immunization, Cyclophosphamide, Cytoxan, Neosar, Fludarabine, Fludarabine Phosphate, Fludara, T-Cells, Interleukin-2, IL-2, Proleukin, Mesna, Sodium 2-mercaptoethanesulfonate, Mesnum, Mesnex, NSC-113891, Intrathecal T-Cells, Intrathecal Interleukin-2
M.D. Anderson Cancer Center, Prometheus Laboratories, Key Biologics, LLC, National Cancer Institute (NCI), Adelson Medical Research
Melanoma
02/30
02/30
NCT06237881: A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Active, not recruiting
1/2
15
US
KSQ-001EX, Interleukin-2, IL-2, Cyclophosphamide, Fludarabine
M.D. Anderson Cancer Center, KSQ Therapeutics, Inc.
Advanced Solid Tumor, Melanoma, Lung Neoplasms, Head and Neck Neoplasms
01/27
01/29
NCT06598371: A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

Recruiting
1/2
141
US
Cyclophosphamide, Fludarabine, KSQ-004EX, Interleukin-2, IL-2
M.D. Anderson Cancer Center, KSQ Therapeutics, Inc.
Select Advanced Solid Tumors
08/39
08/41
Agni-01, NCT06060613: Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Recruiting
1/2
52
US
OBX-115
Obsidian Therapeutics, Inc.
Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
10/25
10/27
Nautilus, NCT05340621: NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

Completed
1/2
36
US
OKI-179 + binimetinib
OnKure, Inc.
RAS Mutation, NRAS Gene Mutation, Melanoma
01/25
01/25
Davies, Michael
No trials found
Parmar, Simrit
No trials found

Download Options